Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

DFMO: targeted risk reduction therapy for colorectal neoplasia.

Laukaitis CM, Gerner EW.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):495-506. doi: 10.1016/j.bpg.2011.09.007. Review.

2.

Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.

Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW.

Gastroenterology. 2010 Sep;139(3):797-805, 805.e1. doi: 10.1053/j.gastro.2010.06.005. Epub 2010 Jun 9.

3.

Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.

Raj KP, Zell JA, Rock CL, McLaren CE, Zoumas-Morse C, Gerner EW, Meyskens FL.

Br J Cancer. 2013 Feb 19;108(3):512-8. doi: 10.1038/bjc.2013.15. Epub 2013 Jan 22.

4.

Development of difluoromethylornithine (DFMO) as a chemoprevention agent.

Meyskens FL Jr, Gerner EW.

Clin Cancer Res. 1999 May;5(5):945-51. Review.

5.

Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.

Zell JA, McLaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL.

J Natl Cancer Inst. 2010 Oct 6;102(19):1513-6. doi: 10.1093/jnci/djq325. Epub 2010 Aug 26.

6.

Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.

Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL.

Cancer Prev Res (Phila). 2009 Mar;2(3):209-12. doi: 10.1158/1940-6207.CAPR-08-0203. Epub 2009 Mar 3.

7.

Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.

Zell JA, Lin BS, Madson N, McLaren CE, Gerner EW, Meyskens FL.

Cancer Causes Control. 2012 Oct;23(10):1739-44. doi: 10.1007/s10552-012-0051-6. Epub 2012 Aug 21.

8.

Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.

Meyskens FL Jr, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W.

J Natl Cancer Inst. 1998 Aug 19;90(16):1212-8.

9.

Chemoprevention for colorectal cancer.

Krishnan K, Ruffin MT 4th, Brenner DE.

Crit Rev Oncol Hematol. 2000 Mar;33(3):199-219. Review. No abstract available.

PMID:
10789493
10.

Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.

Rial NS, Meyskens FL, Gerner EW.

Essays Biochem. 2009 Nov 4;46:111-24. doi: 10.1042/bse0460008. Review.

11.
12.

Chemoprevention of colorectal cancer: systematic review and economic evaluation.

Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P.

Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Review.

13.

Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention.

Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS; Members of the UKCAP Consortium.

Clin Cancer Res. 2008 Apr 15;14(8):2303-9. doi: 10.1158/1078-0432.CCR-07-4599.

14.

A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.

Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K, Pomplun M, Verma AK.

Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):989-92.

15.

Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia.

Mitchell MF, Tortolero-Luna G, Lee JJ, Hittelman WN, Lotan R, Wharton JT, Hong WK, Nishioka K.

Clin Cancer Res. 1998 Feb;4(2):303-10.

17.

Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?

Gill S, Sinicrope FA.

Semin Oncol. 2005 Feb;32(1):24-34. Review.

PMID:
15726503
18.

Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.

Carbone PP, Douglas JA, Larson PO, Verma AK, Blair IA, Pomplun M, Tutsch KD.

Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):907-12.

19.

Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine.

Meyskens FL Jr, Simoneau AR, Gerner EW.

Recent Results Cancer Res. 2014;202:115-20. doi: 10.1007/978-3-642-45195-9_14.

PMID:
24531785
20.

Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.

Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H.

Cancer Res. 2000 Sep 15;60(18):5125-33.

Supplemental Content

Support Center